Methylprednisolone aceponate for atopic dermatitis

Abstract

Most patients with AD can be easily brought into control with the use of only TCS. Achieving a complete healing of eczema is key in AD, and once the skin is clinically healthy, emollients can be used according to the physician and patient preferences. Physicians should be trained in the recognition of early or subtle manifestations of active eczema that are most suitably treated with topical TCS to achieve a most rapid and satisfactory control of the disease. If the whole area with eczema is not treated, active eczema will remain and treatment will be ineffective. Insufficient use of TCS will lead to inefficiency and frustration.

A novel triple combination in treatment of melasma: Significant outcome with far less actives

“…As a fourth generation TC, MPA is included in the potent group. Several clinical studies supporting the use of 0.1% MPA with minimal local or systemic adverse effects have been reported . Compared with traditional TCs, MPA has an enhanced therapeutic index …”

“…6 the use of 0.1% MPA with minimal local or systemic adverse effects have been reported. 7 Compared with traditional TCs, MPA has an enhanced therapeutic index. 8,9 Salicylic acid (SA) is a lipid-soluble compound which is described as both a beta-hydroxy acid and a phenolic aromatic acid by different authors.…”

Atopic Dermatitis: Early Treatment in Children

“…Patient preference (vehicle, cost, and availability), lesion site, and disease severity often drive selection in prescribing and selecting potency of TCS. TCS are well-studied in pediatric patients, and have proven to be safe and effective in reducing the clinical signs and symptoms of AD [58]. Fluticasone propionate 0.05% cream, desonide 0.05% gel and foam, and hydrocortisone butyrate 0.1% lotion are the only topical corticosteroids that are U.S. Food and Drug Administration (FDA) approved for use in infants as young as three months of age.…”

The Role of Topical Glucocorticosteroid Methylprednisolone Aceponate in External Therapy of Atopic Dermatitis in Children

“…Противовоспалительная активность позволяет МПА быстро и эффективно купировать обострение АтД, что продемонстрировано в рандомизированных исследованиях у детей и взрослых [20,21].…”

“…Одним из местных побочных эффектов препарата является атрофия кожи. Антипролиферативная активность глюкокортикостероидов в отношении кератиноцитов и фибробластов приводит к истончению эпидермиса и дермы [21]. Истончение эпидермиса частично обратимо, чего нельзя сказать об атрофии дермы.…”